Precision medicine for breast cancer: advances and challenges.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Gold and silver nanoparticles for safe and effective biomedical applications.Discover nano · 2026
   Review
2. Investigating the role of MYLK2 in breast cancer prognosis and assessing its clinical application value.Scientific reports · 2025
   Article
3. Machine Learning Models Utilizing Oxidative Stress Biomarkers for Breast Cancer Prediction: Efficacy and Limitations in Sentinel Lymph Node Metastasis Detection.Biomedicines · 2025
   Article
4. Lynch Syndrome-Impact of the Type of Deficient Mismatch Repair Gene Mutation on Diagnosis, Clinical Presentation, Surveillance and Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2025
   Review
5. From Bench to Bedside in Emerging Therapies for Gynecological Malignancies: A Narrative Review.Cancer control : journal of the Moffitt Cancer Center
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as